A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. - Wikidata - awgldk - TriplyDB

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

http://www.wikidata.org/entity/Q33523428

about

Computerized advice on drug dosage to improve prescribing practice Systemic therapies for pancreatic cancer--the role of pharmacogenetics Irinotecan pharmacogenomics Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.CYP3A activity: towards dose adaptation to the individual.Sequential designs for individualized dosing in phase I cancer clinical trials.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs.Use of microdose phenotyping to individualise dosing of patients.Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.Integrating rare genetic variants into pharmacogenetic drug response predictions.

P2860

Q24202497-1FF0CE10-D91A-4FAE-B93D-CACE6E43FB68 Q27021716-06C54385-98AC-41EF-A913-294943EB78ED Q28287024-7C4999AA-3DE0-4986-8266-FA455D9799CF Q33420524-E688E8DA-5AF6-4DA3-AD4D-A73DFAA54CD6 Q33712655-1E019B01-4C44-487B-88C0-06C8303A3E38 Q35903844-BC5AF7DE-1F26-4909-8972-3B3623A531E7 Q36510493-3FCC2A1B-AA3A-4C9A-ADFF-59ED1CDB4D77 Q37331793-B7E9745C-2D3C-47AB-B39F-AD5C01FE7D2B Q37876401-E08E3895-0FB5-4C21-A967-31F0CEF1FB52 Q38763583-682D22CF-FB64-46F5-9B1E-D4A2A0B78492 Q38824605-D925C1A3-947C-41BD-8B21-A3057729C758 Q39566084-E9EBFCD5-671A-4034-99FE-8ACB09EDB294 Q40186641-76E9DC80-8BE7-4B6B-8CF5-A1DE01B7AE2D Q40996401-6AA33C8C-685F-43CE-8E9B-B0089C304C67 Q47376469-595F375B-4173-4E54-B029-0D80135A8F7A Q48098073-B5F784A7-260E-484F-93B6-4A0E303D8C8F Q51826210-6AE44EAD-3547-4CBA-BD5B-D4B32156312D Q52362144-6B99979A-5CFE-457F-BEED-495A6A4A5B29 Q53826969-FBA18ADA-ADC0-423F-8ED4-14283F6F77C2 Q54940794-12139A3F-7E45-4402-AB46-844A2BAFCD25

P2860

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

http://www.wikidata.org/entity/Q33523428

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@ast

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@en

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@nl

type

label

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@ast

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@en

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@nl

prefLabel

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@ast

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@en

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@nl

P1433

Q33523428-D473B974-94F8-43AA-9694-D001A2F5A4AC

P1476

Q33523428-6FA57E0C-E1DF-4B5F-9DC1-DB34A40C2976

P2093

Q33523428-0AF2631B-59ED-4307-AC1E-92099D0EDF70

Q33523428-150D3E41-15F3-4D70-A7A7-91FD7DC14015

Q33523428-3E2EA3A5-1955-4EC2-8ACA-7D37907B044B

Q33523428-84A1ABCE-75A1-41F3-AD7B-E38B19701663

Q33523428-880CCF36-1654-4090-B244-4F0A6FA6938F

Q33523428-9B51BFE8-8D64-426D-9D26-3B346E9B95AB

Q33523428-C7E2A54D-B81F-4604-A6AE-A7922B4A35B3

Q33523428-FA1B12D6-0302-46AA-A791-43AC608A64B8

Q33523428-FC5A3AD9-E022-42F7-9374-C3AE586C3774

P304

Q33523428-168150B1-5836-48F4-A684-6BE5D1899FA7

P31

Q33523428-39A65321-CCA7-4190-AAE6-8683726CC38C

P356

Q33523428-68AB80E3-29D9-4AB4-8D0D-E07D3EF421C7

P407

Q33523428-530A4869-7029-4D39-ACE0-F3F6868D4777

P433

Q33523428-B6D4B181-22C6-4701-A1B4-1FB568B96B02

P478

Q33523428-890B7FD1-413D-41F7-AE60-287B3759FA31

P50

Q33523428-AA79A863-C36B-4BA2-BA24-E801AFAF9E2B

P577

Q33523428-82BF8250-F4EA-4134-A44A-4A3A19A5E137

P5875

Q33523428-D3039D6C-9A84-4BD6-A70C-004318301228

P698

Q33523428-9C775A37-E16D-4B21-9D25-06A4657EC48B

P356

1078-0432.CCR-09-1526

P1433

Clinical Cancer Research

P1476

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

@en

P2093

André S Th Planting

http://www.w3.org/2001/XMLSchema#string

Erik A C Wiemer

http://www.w3.org/2001/XMLSchema#string

Floris A de Jong

http://www.w3.org/2001/XMLSchema#string

Geert-Jan M Creemers

http://www.w3.org/2001/XMLSchema#string

Jaap Verweij

http://www.w3.org/2001/XMLSchema#string

Jessica M van der Bol

http://www.w3.org/2001/XMLSchema#string

Lena E Friberg

http://www.w3.org/2001/XMLSchema#string

Ron H J Mathijssen

http://www.w3.org/2001/XMLSchema#string

Walter J Loos

http://www.w3.org/2001/XMLSchema#string

P304

736-742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-1526

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Alex Sparreboom

P577

2010-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41000744

http://www.w3.org/2001/XMLSchema#string

P698

20068078

http://www.w3.org/2001/XMLSchema#string